Tenderwize
Zurück zur Suche

Open House Discount Agreement for Ribociclib

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 186 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ribociclib, ATC L01EF02

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

30 / 100

Risikofaktoren

Buyer may replace open-house agreements with exclusive discount contracts during the term, potentially terminating exis...

No guaranteed purchase volumes; financial benefit depends on market share and prescribing behavior.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for pharmaceutical products containing the active ingredient Ribociclib (ATC L01EF02).
  • Agreements cover the period from 01.05.2025 to 30.04.2027 (24 months maximum).
Vollständige Zusammenfassung anzeigen

This is an open-house procedure by AOK Rheinland-Pfalz/Saarland for non-exclusive discount agreements on the active ingredient Ribociclib (ATC L01EF02). The agreement is for a maximum of 24 months, starting 01.05.2025, with monthly accession possibilities. It is explicitly stated as not a public procurement under EU Directive 2014/24/EU, but published for transparency. No estimated value is provided. The procedure is open to all interested pharmaceutical companies with authorized and marketable medicines in Germany. The first submission deadline for a start on 01.05.2025 is 31.03.2025; later submissions can be made monthly. The buyer may replace these open-house agreements with exclusive discount contracts during the term.

Risiken

Buyer may replace open-house agreements with exclusive discount contracts during the term, potentially terminating exis...

No guaranteed purchase volumes; financial benefit depends on market share and prescribing behavior.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Medicines must be authorized and marketable in Germany.
  • Evidence of marketability via Lauer-Taxe listing or DIMDI AMIce database extracts.
  • Participation is open to all pharmaceutical companies; no selection or negotiation.

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria explicitly specified; participation is open to all eligible companies meeting the conditions.

Auftraggeber

Lose (1)

LOT-0001

Open House Discount Agreement for Ribociclib

Non-exclusive discount agreements for Ribociclib (ATC L01EF02) under an open-house model. All interested pharmaceutical companies meeting the eligibility criteria can participate without selection. Contracts last up to 24 months, with start dates on the first of each month. The buyer may replace these with exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Apr 2025 - Apr 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria explicitly specified; participation is open to all eligible companies meeting the conditions.

Frist

Deadline Feb 28, 2027

Vergabedetails

Veröffentlichungsdatum
20 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
184252-2025

Dokumente (1)

Ähnliche Ausschreibungen